PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
12.50%
Similar gross profit growth to GNPX's 14.31%. Walter Schloss would investigate industry dynamics.
No Data
No Data available this quarter, please select a different quarter.
37.48%
R&D growth while GNPX reduces spending. John Neff would investigate strategic advantage.
21.30%
G&A growth less than half of GNPX's 78.31%. David Dodd would verify if efficiency advantage is structural.
100.00%
Marketing expense change of 100.00% while GNPX maintains spending. Bruce Berkowitz would investigate effectiveness.
No Data
No Data available this quarter, please select a different quarter.
32.37%
Operating expenses growth above 1.5x GNPX's 8.75%. Michael Burry would check for inefficiency.
29.39%
Total costs growth above 1.5x GNPX's 8.70%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-12.50%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-30.36%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-29.39%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
14.89%
Other expenses growth while GNPX reduces costs. John Neff would investigate differences.
-30.95%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while GNPX shows 100.00% growth. Joel Greenblatt would examine advantage.
-30.95%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.58%
EPS decline while GNPX shows 18.70% growth. Joel Greenblatt would examine position.
-22.58%
Diluted EPS decline while GNPX shows 18.70% growth. Joel Greenblatt would examine position.
7.95%
Share count reduction exceeding 1.5x GNPX's 33.62%. David Dodd would verify capital allocation.
7.95%
Diluted share reduction exceeding 1.5x GNPX's 33.60%. David Dodd would verify capital allocation.